Kalaris Therapeutics (NASDAQ:KLRS) Releases Earnings Results

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06, FiscalAI reports.

Kalaris Therapeutics Stock Performance

NASDAQ:KLRS traded down $0.07 on Thursday, hitting $1.82. 7,290 shares of the stock were exchanged, compared to its average volume of 127,810. The stock has a market capitalization of $43.44 million, a price-to-earnings ratio of -0.99 and a beta of 0.47. Kalaris Therapeutics has a 52 week low of $1.78 and a 52 week high of $11.88. The company’s 50-day moving average price is $2.63 and its 200 day moving average price is $5.15.

Wall Street Analyst Weigh In

KLRS has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Kalaris Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Read Our Latest Research Report on Kalaris Therapeutics

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Pale Fire Capital SE bought a new position in Kalaris Therapeutics in the second quarter valued at approximately $161,000. Velan Capital Investment Management LP raised its position in shares of Kalaris Therapeutics by 38.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares during the last quarter. Sigma Planning Corp acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $41,000. Stonepine Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $122,597. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at $407,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

(Get Free Report)

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina. Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

Further Reading

Earnings History for Kalaris Therapeutics (NASDAQ:KLRS)

Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.